Phase I Pembro and IDO inhibitor combo trial

Dear Brian    I think this is probably the first trial looking at anti-pd1 and an IDO inhibitor. There is data on IPI and the same IDO inhibitor. Dr. Weber had some positive things to say about it at a conference in July. There was a 56% response rate. Here is the link:http://www.primeoncology.org/online_education/solid_tumor/2014/paris-melanoma-webcast/weber-activity.aspx?authenticator=%3CLOGINID%3Ebrentsmorris@epbfi.com%3C/LOGINID%3E%3CDATE%3E9/19/2014%2010:37:21%20AM%3C/DATE%3E%3CUSERTOKEN%3E%3C!%5BCDATA%5BDk2ap87VgXUhAJD2gi/Qn+0VQFs=%5D%5D%3E%3C/USERTOKEN%3E

Dear Brian    I think this is probably the first trial looking at anti-pd1 and an IDO inhibitor. There is data on IPI and the same IDO inhibitor. Dr. Weber had some positive things to say about it at a conference in July. There was a 56% response rate. Here is the link:http://www.primeoncology.org/online_education/solid_tumor/2014/paris-melanoma-webcast/weber-activity.aspx?authenticator=%3CLOGINID%3Ebrentsmorris@epbfi.com%3C/LOGINID%3E%3CDATE%3E9/19/2014%2010:37:21%20AM%3C/DATE%3E%3CUSERTOKEN%3E%3C!%5BCDATA%5BDk2ap87VgXUhAJD2gi/Qn+0VQFs=%5D%5D%3E%3C/USERTOKEN%3E

Dear Brian    I think this is probably the first trial looking at anti-pd1 and an IDO inhibitor. There is data on IPI and the same IDO inhibitor. Dr. Weber had some positive things to say about it at a conference in July. There was a 56% response rate. Here is the link:http://www.primeoncology.org/online_education/solid_tumor/2014/paris-melanoma-webcast/weber-activity.aspx?authenticator=%3CLOGINID%3Ebrentsmorris@epbfi.com%3C/LOGINID%3E%3CDATE%3E9/19/2014%2010:37:21%20AM%3C/DATE%3E%3CUSERTOKEN%3E%3C!%5BCDATA%5BDk2ap87VgXUhAJD2gi/Qn+0VQFs=%5D%5D%3E%3C/USERTOKEN%3E

Interesting.  Seems that most of the IDO studies for melanoma have been combinations.  When I did ipi, it was initially supposed to be for an ipi-IDO combo phase I/II, there were like 2 spots left out of 10 at my trial site, but a few days after signing the trial papers, I found out I was excluded because of my prior TIL (the eligibility criteria were vague when it came to prior immunotherapies…  prior ipi was an exclusion, prior IL-2 was not, and everything else wasn't clear, but the pharma coordinator decided TIL was an exclusion).  I was initially disappointed but once I thought about it, we had started thinking I was just doing ipi, the IDO was a surprise "added bonus", so I ended up doing ipi anyway.  Regardless, good to see another front being opened with IDO and the checkpoint inhibitors.  Thanks for sharing Brian.

Joe

Interesting.  Seems that most of the IDO studies for melanoma have been combinations.  When I did ipi, it was initially supposed to be for an ipi-IDO combo phase I/II, there were like 2 spots left out of 10 at my trial site, but a few days after signing the trial papers, I found out I was excluded because of my prior TIL (the eligibility criteria were vague when it came to prior immunotherapies…  prior ipi was an exclusion, prior IL-2 was not, and everything else wasn't clear, but the pharma coordinator decided TIL was an exclusion).  I was initially disappointed but once I thought about it, we had started thinking I was just doing ipi, the IDO was a surprise "added bonus", so I ended up doing ipi anyway.  Regardless, good to see another front being opened with IDO and the checkpoint inhibitors.  Thanks for sharing Brian.

Joe

Interesting.  Seems that most of the IDO studies for melanoma have been combinations.  When I did ipi, it was initially supposed to be for an ipi-IDO combo phase I/II, there were like 2 spots left out of 10 at my trial site, but a few days after signing the trial papers, I found out I was excluded because of my prior TIL (the eligibility criteria were vague when it came to prior immunotherapies…  prior ipi was an exclusion, prior IL-2 was not, and everything else wasn't clear, but the pharma coordinator decided TIL was an exclusion).  I was initially disappointed but once I thought about it, we had started thinking I was just doing ipi, the IDO was a surprise "added bonus", so I ended up doing ipi anyway.  Regardless, good to see another front being opened with IDO and the checkpoint inhibitors.  Thanks for sharing Brian.

Joe